This is a repository copy of *Obesity modulates the association between systolic blood pressure and albuminuria.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/118403/

Version: Accepted Version

**Article:**
Fotheringham, J., Kawar, B., McKane, W. et al. (1 more author) (2017) Obesity modulates the association between systolic blood pressure and albuminuria. Nephrology Dialysis Transplantation. ISSN 0931-0509

https://doi.org/10.1093/ndt/gfx081

---

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Obesity Modulates the Association between Systolic Blood Pressure and Albuminuria

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Nephrology Dialysis Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>NDT-00105-2017.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article - Clinical Research</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Fotheringham, James; Northern General Hospital, Sheffield Kidney Institute Kawar, Bisher; Sheffield Kidney Institute, Northern General Hospital McKane, William; Northern General Hospital NHS Trust, Sheffield Kidney Institute Ellam, Timothy; University of Sheffield, Department of Cardiovascular Science; Sheffield Kidney Institute, Northern General Hospital</td>
</tr>
<tr>
<td>Keyword list:</td>
<td>blood pressure, CKD, hypertension, obesity, Albuminuria</td>
</tr>
</tbody>
</table>
Dear Professor Zocalli and the NDT Editorial Team,

Many thanks for the opportunity to resubmit our manuscript.

We are grateful to the reviewers for their supportive and helpful comments. We have addressed all the points raised, making all the suggested amendments as detailed in the ‘responses to reviewers’ document.

We hope that our work is now deemed suitable for publication and look forward to your decision.

Thank you again for considering our manuscript.

Yours sincerely

Tim Ellam

On behalf of the authors
Obesity Modulates the Association between Systolic Blood Pressure and Albuminuria

James Fotheringham¹, Bisher Kawar¹, William McKane¹, and Timothy Ellam¹,²

1. Sheffield Kidney Institute, Sheffield, UK.
2. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Corresponding author: Timothy Ellam

Email: T.Ellam@sheffield.ac.uk  Telephone: +44 1142261332  Fax: +44 114 271 1863

Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Medical School, Royal Hallamshire Hospital, Beech Hill Road, Sheffield. S10 2RX

Word count: total with abstract and short summary 31012756

Short title: obesity, systolic BP and albuminuria

Keywords: albuminuria, blood pressure, CKD, haemodynamics, hypertension, obesity, population
Abstract

**Background:** Obesity is associated with albuminuria and incident kidney disease. Increased vulnerability of the glomerular microcirculation to elevated systemic blood pressure is postulated to contribute to adverse effects of obesity on the kidney. We therefore hypothesized that obesity would modulate the association between systolic blood pressure (sBP) and albuminuria.

**Methods:** The relationship between obesity and albuminuria (fractional albumin excretion (FE_{alb}) or albumin:creatinine ratio (ACR)) was modelled using linear/logistic regression in the US National Health and Nutrition Examination Survey 1999-2010 cohorts (N=23,710). Associations between sBP and albuminuria were examined across strata of waist circumference and body mass index (BMI) using interaction terms.

**Results:** Obesity was associated with albuminuria through an interaction with sBP. Among participants in the 4th/5th quintiles of waist circumference each 10mmHg increase in sBP was accompanied by approximately double the increment in FE_{alb} observed among those in quintile 2 (14% versus 7% p<0.001). There was also evidence of a lower sBP threshold for the relationship between sBP and albuminuria in obesity. Whilst FE_{alb} increased with sBP>110mmHg in quintile 5 of waist circumference, in quintile 2 FE_{alb} did not increase until sBP was >130mmHg. Findings were consistent when defining obesity by BMI or waist circumference and when quantifying albuminuria by ACR or FE_{alb}. Assessing albuminuria as the odds ratio of ACR>30mg/g also gave similar results.

**Conclusion:** The interaction between sBP and obesity supports the premise that obesity sensitizes the kidney to increased systemic blood pressure.
Short summary

Obesity has been postulated to predispose to kidney disease through haemodynamic effects, increasing pressure transmission to the glomerular microcirculation. Consistent with this premise, in a representative sample of the US population we report an interaction between obesity and systolic BP in their associations with albuminuria; a given increase in systolic BP was associated with approximately double the increment in albumin excretion in obese versus lean subjects. The association between systolic BP and albuminuria was also evident from a lower systolic BP threshold in obesity. This suggests obesity may sensitize the kidney to hypertensive target organ damage.
Introduction

The global obesity epidemic has major implications for chronic kidney disease (CKD) incidence and outcomes. Obesity predisposes to diabetes and hypertension, but is also itself an independent predictor of incident chronic kidney disease (CKD)\textsuperscript{1-3} and endstage renal disease\textsuperscript{4, 5}. Intrarenal haemodynamic effects of obesity may contribute to this phenomenon; severe obesity is accompanied by glomerular hyperfiltration, reversible after successful bariatric surgery\textsuperscript{6}, whilst filtration fraction increases with BMI even in non-obese subjects\textsuperscript{7}. These observations are consistent with renal afferent arteriolar vasodilation and/or efferent vasoconstriction, potentially placing the glomerular microcirculation at greater risk of injury from elevated systemic arterial pressure\textsuperscript{8}.

Albuminuria is a feature of glomerular hypertension and hypertensive renal target organ damage\textsuperscript{9, 10}. In keeping with its postulated haemodynamic effects, obesity has been associated with elevated urine albumin excretion in several cohorts\textsuperscript{11-13}. Furthermore, the heavy proteinuria and focal segmental glomerulosclerosis of obesity-related glomerulopathy are reminiscent of features attributed to glomerular hypertension in the setting of reduced nephron mass\textsuperscript{14, 15}. Although obesity-related glomerulopathy affects only a minority of severely obese patients, it may reflect haemodynamic consequences of obesity that cause overt pathology in the presence of other factors, such as reduced nephron endowment.

Obesity is a major risk factor for hypertension and the two pathologies frequently co-exist. Consequently, if obesity sensitizes the kidney to hypertensive injury this effect could be an important contributor to CKD incidence/progression. We hypothesized that a given systolic blood pressure (sBP) increment would be associated with a greater increase in albuminuria in the presence of obesity. We tested this in a representative sample of the US population: the National Health and Nutrition Examination Survey (NHANES) 1999-2010.

Methods

Study population

The US NHANES uses a multistage sampling strategy to generate a study population representative of the noninstitutionalized US population\textsuperscript{16}. For this analysis non-pregnant participants aged >20y with complete clinical and biochemical data were included from the NHANES cycles 1999-2010. Antihypertensive medication constituents were classified using the Lexicon Plus (Cerner Multum Inc.) drug database. Diabetes mellitus was defined as current use of insulin or oral hypoglycaemic agents, or a response ‘Yes’ to the question, ‘Have you ever been told by a doctor or other health
professional that you have diabetes or sugar diabetes? Other comorbidities and demographic variables were defined as described previously.

Measures of obesity

Although body mass index (BMI) is a well-established measure of body habitus, waist circumference provides a better assessment of obesity-associated health risks. Central body fat distribution has also been reported to be associated with unfavourable renal haemodynamics independently of BMI. Therefore, waist circumference, categorized into gender-specific quintiles, was used as the primary measure of obesity in this study. As a second method of obesity assessment, BMI (calculated as weight/height²) was classified according to World Health Organisation definitions of underweight (BMI<18.5kg/m²), normal (18.5≤BMI<25), overweight (25≤BMI<30), class I obesity (30≤BMI<35) class II obesity (35≤BMI<40) and class III obesity (BMI≥40).

Quantification of albumin leak

Albuminuria is routinely quantified in NHANES as the albumin:creatinine ratio (ACR) in a clean-catch random spot urine sample. A potential confounding factor in this assessment is the greater creatinine excretion rate observed in obesity. Another consideration is the fact that hyperfiltration associated with obesity may drive increased albumin efflux purely by convection in the absence of changes in glomerular pressure or permeability. Therefore, urinary albumin excretion was assessed herein primarily as the fractional excretion of albumin relative to creatinine (FEalb), calculated as: (urine albumin concentration × serum creatinine concentration)/(urine creatinine concentration × serum albumin concentration). This is a measure of total renal albumin permeability that is not confounded by creatinine excretion rate. ACR was used as a secondary assessment in continuous analyses and to categorize according to the established threshold of moderately increased albuminuria (ACR≥30mg/g).

Blood pressure

Blood pressure was measured in a sitting position using a mercury sphygmomanometer after 5 minutes quiet resting. Three pairs of systolic/diastolic BP measurements were taken and a fourth attempted if ≥1 were unsuccessful. The average of the readings was calculated, with exclusion of the first successful reading. Where only 1 reading was successful, this was taken as the average. The postulated interaction between obesity and BP was examined in terms of the systolic BP since this component is the major determinant of renal target organ damage and is mostly consistently associated with albumin leak.
Statistical analyses

This report is a cross-sectional analysis of data collected at single timepoints from participants in successive NHANES cycles. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) with incorporation of participant sample weights. Taylor series linearization was used for estimation of standard errors, accounting for the multistage sampling design. Characteristics of the US population represented by NHANES participants were compared across strata of obesity by linear and logistic regression for means and proportions, respectively. Log-transformation was applied to ACR and FE_{albumin} (both positively skewed) prior to parametric analyses.

Associations between obesity and measures of albumin leak (log-transformed FE_{albumin} and ACR) were examined by univariate linear regression. Adjustment was then performed a priori for relevant covariates: age, sex, race, systolic and diastolic BP, diabetes mellitus, eGFR, smoking status, C-reactive protein (CRP), number of antihypertensives, use of angiotensin-converting enzyme inhibitors (ACEi), use of angiotensin receptor blockers (ARB), use of renin inhibitors, and history of cardiovascular disease. We previously reported that 2-slope linear regression best captured the relationship between BP and log-transformed albumin leak in this population, so the same approach was adopted here, with inflection points at 110mmHg and 70mmHg for systolic and diastolic BP respectively. Interaction terms for diabetes x sBP and eGFR category x sBP were included because there were known to be significant interactions between these variables. To determine whether obesity alters the relationship between sBP and albumin leak, an interaction term for waist circumference quintile x sBP (or BMI category x sBP) was entered into the model, retaining waist circumference quintile (or BMI category) as a separate variable. Interactions with sBP were modelled specifically at ≥110mmHg using the 2-slope regression model.

To investigate whether obesity lowers the sBP threshold from which BP increments are associated with albuminuria, associations were examined for categories of obesity across 10mmHg sBP intervals. Odds ratios of moderately increased albuminuria (ACR≥30mg/g) were also calculated for quintiles of waist circumference or categories of BMI, adjusting for other covariates as above.

Results

Population characteristics

Characteristics of the US population represented by the NHANES 1999-2010 participants are presented by quintiles of waist circumference in Table 1. Overall, 51.5% and 32.5% were classified as obese by waist circumference (>88cm in women and >102cm in men) and BMI (≥30kg/m^2) criteria.
respectively. Increasing waist circumference was associated with higher sBP, diastolic BP, pulse pressure and CRP, greater prevalence of diabetes, eGFR<60ml/min/1.73m², antihypertensive use and cardiovascular disease, but a lower prevalence of smoking. The same pattern of associations was observed when participants were compared across categories of BMI (Table S1, Supplementary Material).

**Associations between measures of obesity and renal albumin leak**

In univariate analyses, FE_alb, ACR and the prevalence of ACR≥30mg/g were lowest in quintile 2 of waist circumference (88.0-95.9cm in men and 79.8-88.0cm in women, Tables 1 and 2); this and ‘normal’ BMI (18.5≤BMI<25kg/m²) served as reference categories. Compared with these reference groups, increasing waist circumference (>95.9cm in men, >88cm in women) and obese categories of BMI (≥30kg/m²) were associated with a statistically significant, progressively greater log-transformed FE_alb and ACR (Table 2 and Table S2, Supplementary Material). When adjusted for relevant covariates only quintile 5 of waist circumference and the most severely obese BMI category (>40kg/m²) remained positively associated with FE_alb and ACR. The underweight BMI category and quintile 1 of waist circumference were both associated with greater FE_alb and ACR in multivariate adjusted analyses. Quantifying albumin leak in terms of the odds ratios of moderately increased ACR (>30mg/g) also gave covariate-adjusted associations that were evident for both extremes of body habitus (shown for waist circumference in Figure 1A).

**Interaction between systolic BP and obesity**

We previously reported that FE_alb and ACR increase exponentially with sBP from a threshold of 110mmHg in this cohort. Therefore, to determine whether sBP plays a role in the association between obesity and albumin leak, the above analyses were repeated stratified by sBP<110mmHg (n=5,564) and ≥110mmHg (n=18,146). The association between obesity and urine albumin leak was confined to patients with sBP≥110mmHg (shown for ACR>30mg/g in Figure 1B).

To test formally whether sBP has a different relationship with albuminuria in the presence of obesity, interaction terms for waist circumference quintile x sBP and BMI category x sBP were entered in the respective regression models for the whole cohort. When these terms were introduced, the association between obesity and albuminuria in isolation was neutralized, being absorbed by the varying effect of sBP across obesity groups (Table 2 and Table S2, Supplementary Material). Significant interactions between obesity and sBP were evident for waist circumference quintiles 4/5 and at BMI≥35kg/m². Thus, a given sBP increment was associated with a greater increase in renal albumin leak at this level of obesity than for quintile 2 and normal BMI respectively.
Illustrating this by back-transforming the results of the linear regression, each 10mmHg increase in sBP was accompanied by exponential covariate-adjusted increases in FE_{alb} of 7%, 8%, 10% and 14% within waist circumference quintiles 2, 3, 4 and 5 respectively. The findings were consistent for both measures of obesity and for both assessments of albumin leak. Covariate-adjusted relationships between sBP, measures of obesity and FE_{alb} are shown in Figure 2 and Table 3.

The interaction between obesity and sBP was independent of the previously reported interaction between diabetes and sBP. Relative contributions of these interactions to the sBP-FE_{alb} relationship are illustrated in Figure 2C. To exclude residual confounding from diabetes or antihypertensive use, the regression analyses were repeated with exclusion of diabetic participants or those taking antihypertensives; the findings were unchanged. Since undiagnosed diabetes might be another confounding factor, the analyses were repeated replacing quintile of glycated haemoglobin for diabetes status and with an interaction term for glycated haemoglobin quintile x sBP; this also did not change the findings. Progressively greater percentage increases in albuminuria per 10mmHg increase in sBP with increasing obesity or diabetes are shown in Table 3 and Figure S1 of the Supplementary Material.

In contrast to the interaction between sBP and obesity, there was no significant interaction with underweight (BMI<18.5kg/m^2 and waist circumference quintile 1). Including the interaction terms thus had little effect on the association of underweight with albuminuria.

**Effect of obesity on the sBP threshold associated with albuminuria**

Having demonstrated an interaction between obesity and sBP, we next assessed whether obesity lowers the threshold at which increasing sBP is associated with greater albumin excretion. To this end, covariate-adjusted albumin leak was examined across categories of sBP and obesity. For quintile 5 of waist circumference and BMI>35kg/m^2, a progressive increase in albumin leak accompanied increments in sBP from 110mmHg. However, for the rest of the population albuminuria did not increase until sBP was >130mmHg (shown for reference categories and severely obese populations in Figure 3A-2A-B). Conclusions were similar when albuminuria was assessed as the odds ratio of ACR≥30mg/g (Supplementary Figure 4S2). In light of this difference in thresholds the piecewise regression models were refined, with inflection points at 110mmHg for quintile 5 of waist circumference and BMI>35kg/m^2, but at 130mmHg for less obese categories. This improved the performance (R^2 and RMSE) of each model. The outputs of the final models are shown in Figure 23C-D. Besides the left shift of the sBP threshold associated with increasing albuminuria, model conclusions were as above; no association between obesity and albuminuria per se (the same Y-intercept for all obesity categories), but a steeper relationship between sBP and albuminuria in the
presence of obesity. The overall increase in albuminuria associated with sBP over the 110-180mmHg range was approximately twice as much in the presence of obesity.

Discussion

Obesity and hypertension are epidemics of the twenty-first century and contributors to the increasing global burden of CKD. We find that in severe obesity a given increment in systolic BP is associated with approximately double the increase in urinary albumin excretion observed in lean subjects. Obesity and hypertension thus may contribute synergistically to CKD. These findings are consistent with a previous small case-control study reporting a steeper relationship between sBP and urinary albumin excretion rate in overweight/obesity versus normal BMI. We find a significant interaction is evident in the top 2 quintiles of waist circumference, i.e. affecting 40% of the US adult population.

Whilst our observational data do not prove a causative relationship between the obesity-sBP interaction and urine albumin leak, they are in keeping with BP-sensitizing effects of obesity on the kidney. Postulated underlying mechanisms include impaired renal afferent arteriolar autoregulation would allow glomerular hypertension to occur at a lower systemic BP, though it is unknown whether obesity alone predisposes to autoregulatory impairment. The increased filtration fraction in obesity could also result from preferential efferent arteriolar vasoconstriction, increasing glomerular capillary pressure at a given systemic sBP. Alternative possible explanations for glomerular vulnerability to sBP in obesity include, a greater glomerular capillary radius (translating hydrostatic pressure to higher wall stress) (according to the Laplace equation), and a reduced density of supporting podocytes, both potential consequences of glomerular hypertrophy.

An association between obesity and albuminuria has been reported previously and a number of non-haemodynamic mechanisms of obesity-induced kidney injury have been proposed. However, adjusting for the systolic BP-obesity interaction in this NHANES analysis completely abolished the association between obesity per se and albuminuria. This observation suggests haemodynamic mechanisms are key to the obesity-albuminuria relationship. It is also consistent with animal data reporting that hypertension is needed for the nephrotoxic consequences of obesity.

Other recent publications have emphasized a requirement for metabolic syndrome comorbidities in mediating the obesity-associated risk of hypertension and CKD. In the absence of metabolic syndrome comorbidities (elevated triglycerides, low HDL cholesterol, hypertension, or impaired glucose tolerance), higher BMI was actually associated with a lower risk of ESRD and no increase in the risk of incident CKD. These findings support the concept of ‘metabolically healthy’
obesity' and contrast with previous reports that obesity is a predictor of ESRD and CKD even in analyses adjusted for other metabolic factors\(^1\,\,2\,\,4\). Synergistic interactions between obesity and other risk factors, such as we describe for sBP, would explain this apparent discrepancy.

Most obese NHANES participants had low level albuminuria (ACR<30mg/g). Nevertheless, given the increased risk of adverse renal outcomes associated with even small increments in albumin excretion rate\(^35\), a causal role for the obesity-sBP interaction in increasing albuminuria could have important implications for CKD prevention/management. In this respect our findings are consistent with observations from the Hunt 1 cohort, where there was a synergistic interaction between increasing BMI and BP in the prediction of ESRD and CKD-associated death\(^5\). Furthermore, prehypertension (BP 120-139/80-89) only predicted an increased risk of these outcomes in the presence of obesity, suggesting obesity had a BP-sensitizing effect\(^5\).

Current guidelines do not advocate lower BP targets in obesity\(^10\). Post-hoc analyses of antihypertensive trials might shed light on whether obese participants gain particular nephroprotective benefit from antihypertensive therapy or a lower systolic BP target. Targeting glomerular capillary hydrostatic pressure through preferential use of renin-angiotensin system (RAS) inhibitors in hypertensive obese patients also might be helpful. Indeed, a post-hoc analysis of the REIN study reported greater antiproteinuric effects and attenuation of CKD progression by ramipril in overweight and obese participants\(^36\). However, the optimal nephroprotective approach to BP management in obese patients would ideally be defined by prospective interventional studies conducted specifically in this population. However, another study of obese, hypertensive, non-proteinuric patients with preserved excretory function found no evidence of benefit associated with RAS-inhibition compared to other antihypertensives. The optimal nephroprotective approach to BP management in obesity thus remains to be determined.

A j-shaped association between BMI and proteinuria has been reported previously\(^37\,\,38\) and was also evident in this NHANES cohort. Whereas the association between obesity and albuminuria was abolished by adjustment for covariates and the systolic BP interaction, that between low BMI (or waist circumference) and albumin leak was not. The underlying explanation for this association is unclear. Unmeasured comorbidity and inflammation may be responsible, though CRP was in fact lowest in the underweight BMI category.

A limitation of our study is the lack of timed urine collections. Since creatinine excretion rate increases with BMI and waist circumference the association between obesity and albumin leak may be underestimated by ACR, whilst that between underweight and ACR could be inflated. We therefore used FE\(_{\text{alb}}\) as the primary measure of albumin leak though the conclusions were the same when either measure was applied. Obesity has been reported to be associated with a small (<10%)
increase in the fractional excretion of creatinine relative to inulin, which will slightly lower the fractional excretion of albumin relative to creatinine. There is no reason, however, to suppose that these measurement issues would affect the observed interaction between sBP and obesity.

In conclusion, our demonstration of an interaction between obesity and systolic BP in their associations with albuminuria suggests the two pathologies may synergize to contribute to CKD. Advising obese hypertensive patients to engage with weight loss programmes is already recommended on the grounds that this can improve BP control and metabolic profile\textsuperscript{10}. Our findings raise the possibilities that weight loss might also reduce vulnerability to hypertensive injury and that nephroprotective benefits of BP control may be greater in obesity.

Acknowledgements

The authors thank the NHANES participants, staff and investigators.

Supplementary Material

Supplementary data are available online at http://ndt.oxfordjournals.org.

Conflict of Interest Statement

All authors have no conflicts of interest to declare. The results presented in this paper have not been published previously in whole or part.

References


Table 1. Characteristics of the US population represented by NHANES 1999-2010 participants, by waist circumference quintile (N=23,710).

<table>
<thead>
<tr>
<th>Variable</th>
<th>1 (reference)</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample, n</td>
<td>4162</td>
<td>4534</td>
<td>4880</td>
<td>5117</td>
<td>5017</td>
</tr>
<tr>
<td>Age, y</td>
<td>38.6 (0.3)</td>
<td>44.5 (0.3)</td>
<td>48.4 (0.3)</td>
<td>50.8 (0.3)</td>
<td>50.4 (0.3)</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>69.7 (1.3)</td>
<td>71.7 (1.3)</td>
<td>72.3 (1.5)</td>
<td>75.0 (1.6)</td>
<td>75.1 (1.4)</td>
</tr>
<tr>
<td>Black</td>
<td>10.9 (0.7)</td>
<td>8.2 (0.6)</td>
<td>8.9 (0.7)</td>
<td>9.3 (0.7)</td>
<td>12.2 (0.9)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11.9 (0.9)</td>
<td>14.1 (1.0)</td>
<td>14.3 (1.2)</td>
<td>12.9 (1.3)</td>
<td>9.5 (1.0)</td>
</tr>
<tr>
<td>Other</td>
<td>7.5 (0.6)</td>
<td>6.0 (0.6)</td>
<td>4.5 (0.5)</td>
<td>2.8 (0.3)</td>
<td>3.3 (0.4)</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>115.5 (0.4)</td>
<td>119.2 (0.3)</td>
<td>122.9 (0.4)</td>
<td>125.3 (0.3)</td>
<td>126.3 (0.4)</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>70.4 (0.2)</td>
<td>71.9 (0.2)</td>
<td>72.5 (0.3)</td>
<td>73.2 (0.3)</td>
<td>73.8 (0.3)</td>
</tr>
<tr>
<td>Pulse pressure, mmHg</td>
<td>46.8 (0.3)</td>
<td>48.8 (0.3)</td>
<td>51.1 (0.4)</td>
<td>52.8 (0.3)</td>
<td>53.2 (0.3)</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73m²</td>
<td>101.0 (0.5)</td>
<td>95.5 (0.4)</td>
<td>92.0 (0.5)</td>
<td>90.3 (0.5)</td>
<td>90.8 (0.4)</td>
</tr>
<tr>
<td>eGFR&lt;60ml/min/1.73m², %</td>
<td>2.4 (0.2)</td>
<td>4.5 (0.4)</td>
<td>7.2 (0.4)</td>
<td>8.0 (0.4)</td>
<td>8.4 (0.4)</td>
</tr>
<tr>
<td>ACR≥30mg/g, %</td>
<td>6.8 (0.5)</td>
<td>5.8 (0.4)</td>
<td>7.9 (0.5)</td>
<td>9.6 (0.5)</td>
<td>13.1 (6.2)</td>
</tr>
<tr>
<td>ACR, mg/g</td>
<td>6.9 (6.8, 7.2)</td>
<td>6.6 (6.4, 6.7)</td>
<td>7.3 (7.1, 7.5)</td>
<td>7.8 (7.6, 8.0)</td>
<td>9.3 (9.0, 9.6)</td>
</tr>
<tr>
<td>FE_{alb} x10⁻⁷</td>
<td>13.3 (12.9, 13.7)</td>
<td>12.9 (12.6, 13.3)</td>
<td>14.8 (14.3, 15.2)</td>
<td>16.0 (15.5, 16.5)</td>
<td>19.6 (18.9, 20.3)</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>2.0 (0.3)</td>
<td>3.4 (0.3)</td>
<td>5.5 (0.4)</td>
<td>8.8 (0.5)</td>
<td>17.3 (0.6)</td>
</tr>
<tr>
<td>Smoker, %</td>
<td>36.6 (1.2)</td>
<td>29.3 (0.9)</td>
<td>27.2 (0.9)</td>
<td>26.4 (0.9)</td>
<td>25.4 (0.9)</td>
</tr>
<tr>
<td>CVD, %</td>
<td>2.2 (0.2)</td>
<td>4.0 (0.4)</td>
<td>5.2 (0.4)</td>
<td>8.2 (0.4)</td>
<td>9.0 (0.5)</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>0.20 (0.01)</td>
<td>0.28 (0.01)</td>
<td>0.38 (0.01)</td>
<td>0.43 (0.01)</td>
<td>0.69 (0.02)</td>
</tr>
<tr>
<td>Antihypertensive use, %</td>
<td>6.9 (0.5)</td>
<td>13.9 (0.6)</td>
<td>21.5 (0.7)</td>
<td>31.0 (0.9)</td>
<td>42.1 (0.9)</td>
</tr>
</tbody>
</table>

Data presented as mean (SE) and % (SE) unless otherwise indicated. (Note different numbers in each category because quintiles defined incorporating sampling weights.)

· Geometric mean (95%CI); positively skewed and log-transformed for linear regression.

· p<0.05, ·p<0.01, ·p<0.005, ·p<0.001, compared to quintile 2.
Table 2. Associations between measures of obesity and FE$_{\text{alb}}$.

<table>
<thead>
<tr>
<th>Waist circumference model</th>
<th>Standard models</th>
<th>Multivariate interaction model$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariate</td>
<td>Multivariate$^a$ (main effects)</td>
</tr>
<tr>
<td>Systolic BP (10mmHg)$^c$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quintile 1</td>
<td>1.03 (0.99, 1.08) p=0.18</td>
<td>1.13 (1.08, 1.18) p&lt;0.001</td>
</tr>
<tr>
<td>Quintile 3</td>
<td>1.14 (1.05, 1.20) p&lt;0.001</td>
<td>1.03 (0.99, 1.07) p=0.14</td>
</tr>
<tr>
<td>Quintile 4</td>
<td>1.24 (1.18, 1.29) p&lt;0.001</td>
<td>1.02 (0.98, 1.06) p=0.34</td>
</tr>
<tr>
<td>Quintile 5</td>
<td>1.51 (1.44, 1.59) p&lt;0.001</td>
<td>1.13 (1.08, 1.18) p&lt;0.001</td>
</tr>
</tbody>
</table>

| Waist Quintile$^d$        |                 |                                 |                                           |
| Systolic BP (10mmHg)$^c$  |                 |                                 |                                           |
| Quintile 1                | 1.09 (1.07, 1.12) p<0.001 | 1.07 (1.04, 1.10) p<0.001 |                                           |
| Quintile 3                | 1.13 (1.08, 1.18) p<0.001 | 1.11 (1.06, 1.17) p<0.001 | 1.01 (0.98, 1.04) p=0.63 |
| Quintile 4                | 1.02 (0.97, 1.07) p=0.48 | 1.01 (0.98, 1.04) p=0.39 |                                           |
| Quintile 5                | 1.07 (1.03, 1.10) p<0.001 |                                           |                                           |

| BMI model$^e$             |                 |                                 |                                           |
| Systolic BP (10mmHg)$^c$  |                 |                                 |                                           |
| BMI<18.5                  | 1.45 (1.29, 1.64) p<0.001 | 1.54 (1.38, 1.73) p<0.001 | 1.58 (1.38, 1.80) p<0.001 |
| 25≤BMI<30                 | 0.91 (0.88, 0.94) p<0.001 | 0.89 (0.86, 0.93) p<0.001 | 1.02 (0.99, 1.04) p=0.19 |
| 30≤BMI<35                 | 0.95 (0.91, 0.99) p=0.014 | 0.92 (0.87, 0.97) p=0.004 | 1.03 (0.99, 1.06) p=0.11 |
| 35≤BMI<40                 | 1.01 (0.95, 1.08) p=0.71 | 0.90 (0.83, 0.98) p=0.01 | 1.08 (1.03, 1.13) p<0.001 |
| BMI≥40                    | 1.57 (1.42, 1.72) p<0.001 | 1.15 (1.05, 1.26) p=0.002 | 1.02 (0.91, 1.15) p=0.72 |

$^a$Adjusted for: systolic and diastolic BP (2-slope model), age, gender, race, diabetes, eGFR, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin antagonists, interaction terms for systolic BP x eGFR category and systolic BP x diabetes status.

$^b$As for multivariate standard model, but with the addition of interaction terms for waist circumference x systolic BP or BMI x systolic BP.

$^c$At systolic BP>110mmHg.

$^d$Relative to quintile 2.

$^e$Relative to 18.5≤BMI<25kgm$^2$.

$^f$Relative to 18.5≤BMI<25kgm$^2$.

$^g$Relative to 18.5≤BMI<25kgm$^2$.

$^h$The effect of an increment in systolic BP or the indicated obesity category per se.

$^i$The additional effect of a 10mmHg increment in systolic BP within each obesity category.
Table 3. Percentage increases in fractional excretion of albumin and ACR with increasing blood pressure, stratified by obesity group and diabetes status.

<table>
<thead>
<tr>
<th>Waist circumference quintile</th>
<th>BMI (kg/m²)</th>
<th>% Increase associated with each 10mmHg increment in systolic BP at &gt;110mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Without Diabetes Mellitus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>FEalb</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>ACR</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td></td>
<td>With Diabetes Mellitus*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>FEalb</td>
<td>17%</td>
<td>16%</td>
</tr>
<tr>
<td>ACR</td>
<td>17%</td>
<td>17%</td>
</tr>
</tbody>
</table>

Results from regression models with interaction terms for sBP x obesity category and sBP x diabetes status.

*p<0.05 vs. quintile 2, †p<0.001 vs. quintile 2, ‡p<0.005 vs. 18.5≤BMI<25, §p<0.05 vs. 18.5≤BMI<25,

*p<0.05 vs. non-diabetic categories

Also adjusted for: systolic and diastolic BP (2-slope model), age, gender, race, diabetes, eGFR, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEI, use of ARB, use of renin antagonists, and an interaction terms for systolic BP x eGFR category and systolic BP x diabetes status.
Figure Legends

Figure 1. Odds ratios of moderately increased albuminuria by waist circumference quintile A) in the whole cohort, and B) within subpopulations with systolic BP≥/110mmHg.

Adjusted for age, gender, race, diabetes, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin inhibitors, CRP, diastolic BP, systolic BP (Figure 1A only), and interaction terms for systolic BP with eGFR and diabetes.

ref, referent group; WC, waist circumference. Error bars represent 95% confidence intervals.

Figure 2. Adjusted relationship between systolic BP and fractional albumin excretion according to A) waist circumference quintile, B) BMI, and C) waist circumference quintile and diabetes mellitus.

Outputs are shown for the regression model in the whole cohort, adjusted for age, gender, race, diabetes, diastolic BP, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin inhibitors, CRP and interaction terms for systolic BP with eGFR and diabetes.

Q2, Q4 and Q5 represent gender-specific waist circumference quintiles 2, 4 and 5 respectively in the absence of diabetes.

Q2DM and Q5DM, waist circumference quintiles 2 and 5 in the presence of diabetes.

Figure 32. Effects of obesity on the threshold from which increasing systolic BP is accompanied by increasing albumin excretion. In the 5th quintile of waist circumference (A) or at a BMI≥35kg/m² (B), FE_{alb} increases with systolic BP>110mmHg, whereas for less obese populations (shown for the respective reference categories) there is no increase until systolic BP is >130mmHg. The two-slope regression models for systolic BP were therefore refined, with inflection points at 110mmHg for quintile 5 of waist circumference and BMI≥35kg/m², but at 130mmHg for all other categories.

Outputs of the resulting regression models are shown (C,D).

Adjusted for age, gender, race, diabetes, diastolic BP, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin inhibitors, CRP and interaction terms for systolic BP with eGFR and diabetes.
Figure 1

A whole cohort

Odds Ratio of ACR>30mg/g

Q1 Q2 Q3 Q4 Q5

WC Quintile

B systolic BP≥110mmHg (n=18,146) systolic BP<110mmHg (n=5,564)

Odds Ratio of ACR>30mg/g

Q1 Q2 Q3 Q4 Q5

WC Quintile
Figure 2.

A  

$FE_{\text{ass}} \times 10^6$ vs Systolic BP (mmHg)

Q5
Q4
Q2

B

$FE_{\text{ass}} \times 10^6$ vs Systolic BP (mmHg)

BMI > 35

18.5 < BMI < 25

C

$FE_{\text{ass}} \times 10^6$ vs Systolic BP (mmHg)

Q5DM
Q2DM
Q5
Q2
Figure 32.
Obesity Modulates the Association between Systolic Blood Pressure and Albuminuria

James Fotheringham\(^1\), Bisher Kawar\(^1\), William McKane\(^1\), and Timothy Ellam\(^1,2\)

1. Sheffield Kidney Institute, Sheffield, UK.

2. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Corresponding author: Timothy Ellam

Email: T.Ellam@sheffield.ac.uk Telephone: +44 1142261332 Fax: +44 114 271 1863

Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Medical School, Royal Hallamshire Hospital, Beech Hill Road, Sheffield. S10 2RX

Word count: total with abstract and short summary 2756

Short title: obesity, systolic BP and albuminuria

Keywords: albuminuria, blood pressure, CKD, haemodynamics, hypertension, obesity, population
Abstract

Background: Obesity is associated with albuminuria and incident kidney disease. Increased vulnerability of the glomerular microcirculation to elevated systemic blood pressure is postulated to contribute to adverse effects of obesity on the kidney. We therefore hypothesized that obesity would modulate the association between systolic blood pressure (sBP) and albuminuria.

Methods: The relationship between obesity and albuminuria (fractional albumin excretion (FEalb) or albumin:creatinine ratio (ACR)) was modelled using linear/logistic regression in the US National Health and Nutrition Examination Survey 1999-2010 cohorts (N=23,710). Associations between sBP and albuminuria were examined across strata of waist circumference and body mass index (BMI) using interaction terms.

Results: Obesity was associated with albuminuria through an interaction with sBP. Among participants in the 4th/5th quintiles of waist circumference each 10mmHg increase in sBP was accompanied by approximately double the increment in FEalb observed among those in quintile 2 (14% versus 7% p<0.001). There was also evidence of a lower sBP threshold for the relationship between sBP and albuminuria in obesity. Whilst FEalb increased with sBP>110mmHg in quintile 5 of waist circumference, in quintile 2 FEalb did not increase until sBP was >130mmHg. Findings were consistent when defining obesity by BMI or waist circumference and when quantifying albuminuria by ACR or FEalb. Assessing albuminuria as the odds ratio of ACR>30mg/g also gave similar results.

Conclusion: The interaction between sBP and obesity supports the premise that obesity sensitizes the kidney to increased systemic blood pressure.
**Short summary**

Obesity has been postulated to predispose to kidney disease through haemodynamic effects, increasing pressure transmission to the glomerular microcirculation. Consistent with this premise, in a representative sample of the US population we report an interaction between obesity and systolic BP in their associations with albuminuria; a given increase in systolic BP was associated with approximately double the increment in albumin excretion in obese versus lean subjects. The association between systolic BP and albuminuria was also evident from a lower systolic BP threshold in obesity. This suggests obesity may sensitize the kidney to hypertensive target organ damage.
Introduction

Obesity is an independent predictor of incident chronic kidney disease (CKD)\(^1\)\(^-\)\(^3\) and endstage renal disease\(^4\),\(^5\). Intrarenal haemodynamic effects of obesity may contribute to this phenomenon; severe obesity is accompanied by glomerular hyperfiltration, reversible after successful bariatric surgery\(^6\), whilst filtration fraction increases with BMI even in non-obese subjects\(^7\). These observations are consistent with renal afferent arteriolar vasodilatation and/or efferent vasoconstriction, potentially placing the glomerular microcirculation at greater risk of injury from elevated systemic arterial pressure\(^8\).

Albuminuria is a feature of glomerular hypertension and hypertensive renal target organ damage\(^9\),\(^10\). In keeping with its postulated haemodynamic effects, obesity has been associated with elevated urine albumin excretion in several cohorts\(^11\)-\(^13\). Furthermore, the heavy proteinuria and focal segmental glomerulosclerosis of obesity-related glomerulopathy are reminiscent of features attributed to glomerular hypertension in the setting of reduced nephron mass\(^14\),\(^15\). If obesity sensitizes the kidney to hypertensive injury this effect could be an important contributor to CKD incidence/progression. We hypothesized that a given systolic blood pressure (sBP) increment would be associated with a greater increase in albuminuria in the presence of obesity. We tested this in a representative sample of the US population: the National Health and Nutrition Examination Survey (NHANES) 1999-2010.

Methods

Study population

The US NHANES uses a multistage sampling strategy to generate a study population representative of the noninstitutionalized US population\(^16\). For this analysis non-pregnant participants aged >20y with complete clinical and biochemical data were included from the NHANES cycles 1999-2010. Comorbidities and demographic variables were defined as described previously\(^17\).

Measures of obesity

Although body mass index (BMI) is a well-established measure of body habitus, waist circumference provides a better assessment of obesity-associated health risks\(^18\),\(^19\). Central body fat distribution has also been reported to be associated with unfavourable renal haemodynamics independently of BMI\(^20\). Therefore, waist circumference, categorized into gender-specific quintiles, was used as the primary measure of obesity in this study. As a second method of obesity assessment, BMI (weight/height\(^2\)) was classified according to World Health Organisation definitions\(^21\) of underweight...
(BMI<18.5\text{kg/m}^2), normal (18.5\leq\text{BMI}<25), overweight (25\leq\text{BMI}<30), class I obesity (30\leq\text{BMI}<35) class II obesity (35\leq\text{BMI}<40) and class III obesity (\text{BMI}\geq40).

**Quantification of albumin leak**

Albuminuria is quantified in NHANES as the albumin:creatinine ratio (ACR) in a clean-catch random spot urine sample. A potential confounding factor in this assessment is the greater creatinine excretion rate observed in obesity\textsuperscript{22}. Another consideration is the fact that hyperfiltration associated with obesity may drive increased albumin efflux purely by convection in the absence of changes in glomerular pressure or permeability\textsuperscript{17, 23}. Therefore, urinary albumin excretion was assessed herein primarily as the fractional excretion of albumin relative to creatinine (FE\textsubscript{alb}), calculated as: (urine albumin concentration \times serum creatinine concentration)/(urine creatinine concentration \times serum albumin concentration). This is a measure of total renal albumin permeability\textsuperscript{17} that is not confounded by creatinine excretion rate. ACR was used as a secondary assessment in continuous analyses and to categorize according to the established threshold of moderately increased albuminuria (ACR\geq30\text{mg/g})\textsuperscript{24}.

**Blood pressure**

Blood pressure was measured in a sitting position using a mercury sphygmomanometer after 5 minutes quiet resting. Three pairs of systolic/diastolic BP measurements were taken and a fourth attempted if \geq1 were unsuccessful. The average of the readings was calculated, with exclusion of the first successful reading. Where only 1 reading was successful, this was taken as the average. The postulated interaction between obesity and BP was examined in terms of the systolic BP since this component is the major determinant of renal target organ damage and is mostly consistently associated with albumin leak\textsuperscript{17}.

**Statistical analyses**

This report is a cross-sectional analysis of data collected at single timepoints from participants in successive NHANES cycles. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) with incorporation of participant sample weights\textsuperscript{25}. Taylor series linearization was used for estimation of standard errors, accounting for the multistage sampling design. Characteristics of the US population represented by NHANES participants were compared across strata of obesity by linear and logistic regression for means and proportions, respectively. Log-transformation was applied to ACR and FE\textsubscript{alb} (both positively skewed) prior to parametric analyses.
Associations between obesity and measures of albumin leak were examined by univariate linear regression. Adjustment was then performed \textit{a priori} for relevant covariates: age, sex, race, systolic and diastolic BP, diabetes mellitus, eGFR, smoking status, C-reactive protein (CRP), number of antihypertensives, use of angiotensin-converting enzyme inhibitors (ACEI), use of angiotensin receptor blockers (ARB), use of renin inhibitors, and history of cardiovascular disease. We previously reported that 2-slope linear regression best captured the relationship between BP and log-transformed albumin leak in this population\textsuperscript{17}, so the same approach was adopted here, with inflection points at 110mmHg and 70mmHg for systolic and diastolic BP respectively. Interaction terms for diabetes x sBP and eGFR category x sBP were included because there were known to be significant interactions between these variables\textsuperscript{17}. To determine whether obesity alters the relationship between sBP and albumin leak, an interaction term for waist circumference quintile x sBP (or BMI category x sBP) was entered into the model, retaining waist circumference quintile (or BMI category) as a separate variable. Interactions with sBP were modelled specifically at $\geq 110\text{mmHg}$ using the 2-slope regression model.

To investigate whether obesity lowers the sBP threshold from which BP increments are associated with albuminuria, associations were examined for categories of obesity across 10mmHg sBP intervals. Odds ratios of moderately increased albuminuria (ACR$\geq 30$mg/g) were also calculated for quintiles of waist circumference or categories of BMI, adjusting for other covariates as above.

\section*{Results}

\subsection*{Population characteristics}

Characteristics of the US population represented by the NHANES 1999-2010 participants are presented by quintiles of waist circumference in Table 1. Overall, 51.5\% and 32.5\% were classified as obese by waist circumference (>88cm in women and >102cm in men\textsuperscript{26}) and BMI ($\geq 30$kg/m$^2$) criteria respectively. Increasing waist circumference was associated with higher sBP, diastolic BP, pulse pressure and CRP, greater prevalence of diabetes, eGFR$<60$ml/min/1.73m$^2$, antihypertensive use and cardiovascular disease, but a lower prevalence of smoking. The same pattern of associations was observed when participants were compared across categories of BMI (Table S1, Supplementary Material).

\subsection*{Associations between measures of obesity and renal albumin leak}

In univariate analyses, $\text{FE}_{\text{alb}}$, ACR and the prevalence of ACR$\geq 30$mg/g were lowest in quintile 2 of waist circumference (88.0-95.9cm in men and 79.8-88.0cm in women, Tables 1 and 2); this and
'normal' BMI (18.5 ≤ BMI < 25kg/m²) served as reference categories. Compared with these reference groups, increasing waist circumference (>95.9cm in men, >88cm in women) and obese categories of BMI (≥30kg/m²) were associated with a statistically significant, progressively greater log-transformed FE_{alb} and ACR (Table 2 and Table S2, Supplementary Material). When adjusted for relevant covariates only quintile 5 of waist circumference and the most severely obese BMI category (>40kg/m²) remained positively associated with FE_{alb} and ACR. The underweight BMI category and quintile 1 of waist circumference were both associated with greater FE_{alb} and ACR in multivariate adjusted analyses. Quantifying albumin leak in terms of the odds ratios of moderately increased ACR (>30mg/g) also gave covariate-adjusted associations that were evident for both extremes of body habitus (shown for waist circumference in Figure 1A).

**Interaction between systolic BP and obesity**

We previously reported that FE_{alb} and ACR increase exponentially with sBP from a threshold of 110mmHg in this cohort. Therefore, to determine whether sBP plays a role in the association between obesity and albumin leak, the above analyses were repeated stratified by sBP<110mmHg (n=5,564) and ≥110mmHg (n=18,146). The association between obesity and urine albumin leak was confined to patients with sBP≥110mmHg (shown for ACR>30mg/g in Figure 1B).

To test formally whether sBP has a different relationship with albuminuria in the presence of obesity, interaction terms for waist circumference quintile x sBP and BMI category x sBP were entered in the respective regression models for the whole cohort. When these terms were introduced, the association between obesity and albuminuria in isolation was neutralized, being absorbed by the varying effect of sBP across obesity groups (Table 2 and Table S2, Supplementary Material). Significant interactions between obesity and sBP were evident for waist circumference quintiles 4/5 and at BMI≥35kg/m². Thus, a given sBP increment was associated with a greater increase in renal albumin leak at this level of obesity than for quintile 2 and normal BMI respectively.

The interaction between obesity and sBP was independent of the previously reported interaction between diabetes and sBP. To exclude residual confounding from diabetes or antihypertensive use, the regression analyses were repeated with exclusion of diabetic participants or those taking antihypertensives; the findings were unchanged. Since undiagnosed diabetes might be another confounding factor, the analyses were repeated replacing quintile of glycated haemoglobin for diabetes status and with an interaction term for glycated haemoglobin quintile x sBP; this also did not change the findings. Progressively greater percentage increases in albuminuria per 10mmHg increase in sBP with increasing obesity or diabetes are shown in Table 3 and Figure S1 Supplementary Material.
In contrast to the interaction between sBP and obesity, there was no significant interaction with underweight (BMI<18.5kg/m² and waist circumference quintile 1). Including the interaction terms thus had little effect on the association of underweight with albuminuria.

Having demonstrated an interaction between obesity and sBP, we next assessed whether obesity lowers the threshold at which increasing sBP is associated with greater albumin excretion. To this end, covariate-adjusted albumin leak was examined across categories of sBP and obesity. For quintile 5 of waist circumference and BMI>35kg/m², a progressive increase in albumin leak accompanied increments in sBP from 110mmHg. However, for the rest of the population albuminuria did not increase until sBP was >130mmHg (shown for reference categories and severely obese populations in Figure 2A-B). Conclusions were similar when albuminuria was assessed as the odds ratio of ACR≥30mg/g (Supplementary Figure S2). In light of this difference in thresholds the piecewise regression models were refined, with inflection points at 110mmHg for quintile 5 of waist circumference and BMI>35kg/m², but at 130mmHg for less obese categories. This improved the performance (R² and RMSE) of each model. The outputs of the final models are shown in Figure 2C-D. Besides the left shift of the sBP threshold associated with increasing albuminuria, model conclusions were as above; no association between obesity and albuminuria per se (the same Y-intercept for all obesity categories), but a steeper relationship between sBP and albuminuria in the presence of obesity. The overall increase in albuminuria associated with sBP over the 110-180mmHg range was approximately double in the presence of obesity.

Discussion

Obesity and hypertension are epidemics of the twenty-first century and contributors to the increasing global burden of CKD²⁷, ²⁸. We find that in severe obesity a given increment in sBP is associated with approximately double the increase in urinary albumin excretion observed in lean subjects. Obesity and hypertension thus may contribute synergistically to CKD. These findings are consistent with a previous small case-control study reporting a steeper relationship between sBP and urinary albumin excretion rate in overweight/obesity versus normal BMI²⁹. We find a significant interaction is evident in the top 2 quintiles of waist circumference, i.e. affecting 40% of the US adult population.

Whilst our observational data do not prove a causative relationship between the obesity-sBP interaction and urine albumin leak, they are in keeping with BP-sensitizing effects of obesity on the kidney. Postulated underlying mechanisms include impaired renal afferent arteriolar autoregulation⁸, efferent arteriolar vasoconstriction¹⁹, a greater glomerular capillary radius (translating hydrostatic pressure to higher wall stress)⁸, and a reduced density of supporting...
An association between obesity and albuminuria has been reported previously\textsuperscript{11-13} and a number of non-haemodynamic mechanisms of obesity-induced kidney injury have been proposed\textsuperscript{19,27}. However, adjusting for the sBP-obesity interaction in this NHANES analysis completely abolished the association between obesity \textit{per se} and albuminuria. This observation suggests haemodynamic mechanisms are key to the obesity-albuminuria relationship. It is also consistent with animal data reporting that hypertension is needed for the nephrotoxic consequences of obesity\textsuperscript{31}.

Other recent publications have emphasized a requirement for metabolic comorbidities in mediating the obesity-associated risk of hypertension\textsuperscript{32} and CKD. In the absence of metabolic comorbidities (elevated triglycerides, low HDL cholesterol, hypertension, or impaired glucose tolerance), higher BMI was actually associated with a lower risk of ESRD\textsuperscript{33} and no increase in the risk of incident CKD\textsuperscript{34}. These findings support the concept of 'metabolically healthy obesity' and contrast with previous reports that obesity is a predictor of ESRD and CKD even in analyses adjusted for other metabolic factors\textsuperscript{1,2,4}. Synergistic interactions between obesity and other risk factors, such as we describe for sBP, would explain this apparent discrepancy.

Given the increased risk of adverse renal outcomes associated with even small increments in albumin excretion rate\textsuperscript{35}, a causal role for the obesity-sBP interaction in increasing albuminuria could have important implications for CKD prevention/management. In this respect our findings are consistent with observations from the Hunt 1 cohort, where there was a synergistic interaction between increasing BMI and BP in the prediction of ESRD and CKD-associated death\textsuperscript{5}. Furthermore, prehypertension (BP 120-139/80-89) only predicted an increased risk of these outcomes in the presence of obesity, suggesting obesity had a BP-sensitizing effect\textsuperscript{5}.

Current guidelines do not advocate lower BP targets in obesity\textsuperscript{10}. Post-hoc analyses of antihypertensive trials might shed light on whether obese participants gain particular nephroprotective benefit from antihypertensive therapy or a lower sBP target. Targeting glomerular capillary hydrostatic pressure through preferential use of renin-angiotensin system (RAS) inhibitors in hypertensive obese patients also might be helpful. Indeed, a post-hoc analysis of the REIN study reported greater antiproteinuric effects and attenuation of CKD progression by ramipril in overweight and obese participants\textsuperscript{36}. However, the optimal nephroprotective approach to BP management in obese patients would ideally be defined by prospective interventional studies conducted specifically in this population.

A j-shaped association between BMI and proteinuria has been reported previously\textsuperscript{37,38} and was also evident in this NHANES cohort. Whereas the association between obesity and albuminuria was abolished by adjustment for covariates and the systolic BP interaction, that between low BMI
(or waist circumference) and albumin leak was not. The underlying explanation for this association is unclear. Unmeasured comorbidity and inflammation may be responsible, though CRP was in fact lowest in the underweight BMI category.

In conclusion, our demonstration of an interaction between obesity and systolic BP in their associations with albuminuria suggests the two pathologies may synergize to contribute to CKD. Advising obese hypertensive patients to engage with weight loss programmes is already recommended on the grounds that this can improve BP control and metabolic profile\textsuperscript{10}. Our findings raise the possibilities that weight loss might also reduce vulnerability to hypertensive injury and that nephroprotective benefits of BP control may be greater in obesity.

Acknowledgements

The authors thank the NHANES participants, staff and investigators.

Supplementary Material

Supplementary data are available online at http://ndt.oxfordjournals.org.

Conflict of Interest Statement

All authors have no conflicts of interest to declare. The results presented in this paper have not been published previously in whole or part.

References


Table 1. Characteristics of the US population represented by NHANES 1999-2010 participants, by waist circumference quintile (N=23,710).

<table>
<thead>
<tr>
<th>Variable</th>
<th>1 (reference)</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample, n</td>
<td>4162</td>
<td>4534</td>
<td>4880</td>
<td>5117</td>
<td>5017</td>
</tr>
<tr>
<td>Age, y</td>
<td>38.6 (0.3) e</td>
<td>44.5 (0.3)</td>
<td>48.4 (0.3) e</td>
<td>50.8 (0.3) e</td>
<td>50.4 (0.3) e</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>69.7 (1.3) d</td>
<td>71.7 (1.3)</td>
<td>72.3 (1.5) d</td>
<td>75.0 (1.6) d</td>
<td>75.1 (1.4) d</td>
</tr>
<tr>
<td>Black</td>
<td>10.9 (0.7) e</td>
<td>8.2 (0.6)</td>
<td>8.9 (0.7) e</td>
<td>9.3 (0.7) e</td>
<td>12.2 (0.9) e</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11.9 (0.9) b</td>
<td>14.1 (1.0)</td>
<td>14.3 (1.2) b</td>
<td>12.9 (1.3) b</td>
<td>9.5 (1.0) b</td>
</tr>
<tr>
<td>Other</td>
<td>7.5 (0.6) e</td>
<td>6.0 (0.6)</td>
<td>4.5 (0.5) e</td>
<td>2.8 (0.3) e</td>
<td>3.3 (0.4) d</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>115.5 (0.4) f</td>
<td>119.2 (0.3)</td>
<td>122.9 (0.4) f</td>
<td>125.3 (0.3) f</td>
<td>126.3 (0.4) f</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>68.7 (0.3) f</td>
<td>70.4 (0.2)</td>
<td>71.9 (0.2) f</td>
<td>72.5 (0.3) f</td>
<td>73.2 (0.3) f</td>
</tr>
<tr>
<td>Pulse pressure, mmHg</td>
<td>46.8 (0.3) f</td>
<td>48.8 (0.3)</td>
<td>51.1 (0.4) f</td>
<td>52.8 (0.3) f</td>
<td>53.2 (0.3) f</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73m²</td>
<td>101.0 (0.5) f</td>
<td>95.5 (0.4)</td>
<td>92.0 (0.5) f</td>
<td>90.3 (0.5) f</td>
<td>90.8 (0.4) f</td>
</tr>
<tr>
<td>eGFR&lt;60ml/min/1.73m², %</td>
<td>2.4 (0.2) f</td>
<td>4.5 (0.4)</td>
<td>7.2 (0.4) f</td>
<td>8.0 (0.4) f</td>
<td>8.4 (0.4) e</td>
</tr>
<tr>
<td>ACR≥30mg/g, %</td>
<td>6.8 (0.5) d</td>
<td>5.8 (0.4)</td>
<td>7.9 (0.5) d</td>
<td>9.6 (0.5) d</td>
<td>13.1 (6.2) f</td>
</tr>
<tr>
<td>ACR, mg/g²</td>
<td>6.9 (6.8, 7.2) f</td>
<td>6.6 (6.4, 6.7)</td>
<td>7.3 (7.1, 7.5) f</td>
<td>7.8 (7.6, 8.0) f</td>
<td>9.3 (9.0, 9.6) f</td>
</tr>
<tr>
<td>FEₜₐᵢᵦₐ x10⁻⁷²</td>
<td>13.3 (12.9, 13.7)</td>
<td>12.9 (12.6, 13.3)</td>
<td>14.8 (14.3, 15.2)</td>
<td>16.0 (15.5, 16.5)</td>
<td>19.6 (18.9, 20.3)</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>2.0 (0.3) e</td>
<td>3.4 (0.3)</td>
<td>5.5 (0.4) e</td>
<td>8.8 (0.5) e</td>
<td>17.3 (0.6) e</td>
</tr>
<tr>
<td>Smoker, %</td>
<td>36.6 (1.2) e</td>
<td>29.3 (0.9)</td>
<td>27.2 (0.9) e</td>
<td>26.4 (0.9) e</td>
<td>25.4 (0.9) e</td>
</tr>
<tr>
<td>CVD, %</td>
<td>2.2 (0.2) e</td>
<td>4.0 (0.4)</td>
<td>5.2 (0.4) e</td>
<td>8.2 (0.4) e</td>
<td>9.0 (0.5) e</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>0.20 (0.01) f</td>
<td>0.28 (0.01)</td>
<td>0.38 (0.01) f</td>
<td>0.43 (0.01) f</td>
<td>0.69 (0.02) f</td>
</tr>
<tr>
<td>Antihypertensive use, %</td>
<td>6.9 (0.5) e</td>
<td>13.9 (0.6)</td>
<td>21.5 (0.7) e</td>
<td>31.0 (0.9) e</td>
<td>42.1 (0.9) e</td>
</tr>
</tbody>
</table>

Data presented as mean (SE) and % (SE) unless otherwise indicated. (Note different numbers in each category because quintiles defined incorporating sampling weights.)

**a**Geometric mean (95%CI); positively skewed and log-transformed for linear regression.

**b**p<0.05, **c**p<0.01, **d**p<0.005, **e**p<0.001, compared to quintile 2.
Table 2. Associations between measures of obesity and FE_{alb}.

<table>
<thead>
<tr>
<th></th>
<th>Associated fold-change (95% CI) in FE_{alb}</th>
<th>Standard models</th>
<th>Multivariate interaction model&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Multivariate&lt;sup&gt;a&lt;/sup&gt;</strong></td>
<td><strong>Single Term&lt;sup&gt;c&lt;/sup&gt; (main effects)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Univariate</strong>&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Waist circumference model</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (10mmHg)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-</td>
<td>1.09 (1.07, 1.12) p&lt;0.001</td>
<td>1.07 (1.04, 1.10) p&lt;0.001</td>
</tr>
<tr>
<td>Waist Quintile&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quintile 1</td>
<td>1.03 (0.99, 1.08) p=0.18</td>
<td>1.13 (1.08, 1.18) p&lt;0.001</td>
<td>1.11 (1.06, 1.17) p&lt;0.001</td>
</tr>
<tr>
<td>Quintile 3</td>
<td>1.14 (1.09, 1.20) p&lt;0.001</td>
<td>1.03 (0.99, 1.07) p=0.14</td>
<td>1.02 (0.97, 1.07) p=0.48</td>
</tr>
<tr>
<td>Quintile 4</td>
<td>1.24 (1.18, 1.29) p&lt;0.001</td>
<td>1.02 (0.98, 1.06) p=0.34</td>
<td>0.98 (0.92, 1.03) p=0.38</td>
</tr>
<tr>
<td>Quintile 5</td>
<td>1.51 (1.44, 1.59) p&lt;0.001</td>
<td>1.13 (1.08, 1.18) p&lt;0.001</td>
<td>1.02 (0.96, 1.09) p=0.50</td>
</tr>
<tr>
<td>BMI model&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (10mmHg)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-</td>
<td>1.09 (1.07, 1.12) p&lt;0.001</td>
<td>1.07 (1.04, 1.10) p&lt;0.001</td>
</tr>
<tr>
<td>BMI categories</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI&lt;18.5</td>
<td>1.45 (1.29, 1.64) p&lt;0.001</td>
<td>1.54 (1.38, 1.73) p&lt;0.001</td>
<td>1.58 (1.38, 1.80) p&lt;0.001</td>
</tr>
<tr>
<td>25≤BMI&lt;30</td>
<td>1.00 (0.97, 1.04) p=0.81</td>
<td>0.91 (0.88, 0.94) p&lt;0.001</td>
<td>0.89 (0.86, 0.93) p&lt;0.001</td>
</tr>
<tr>
<td>30≤BMI&lt;35</td>
<td>1.13 (1.08, 1.18) p&lt;0.001</td>
<td>0.95 (0.91, 0.99) p=0.014</td>
<td>0.92 (0.87, 0.97) p=0.004</td>
</tr>
<tr>
<td>35≤BMI&lt;40</td>
<td>1.28 (1.20, 1.37) p&lt;0.001</td>
<td>1.01 (0.95, 1.08) p=0.71</td>
<td>0.90 (0.83, 0.98) p=0.01</td>
</tr>
<tr>
<td>BMI≥40</td>
<td>1.57 (1.42, 1.72) p&lt;0.001</td>
<td>1.15 (1.05, 1.26) p=0.002</td>
<td>1.02 (0.91, 1.15) p=0.72</td>
</tr>
</tbody>
</table>

<sup>a</sup>Adjusted for: systolic and diastolic BP (2-slope model), age, gender, race, diabetes, eGFR, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin antagonists, interaction terms for systolic BP x eGFR category and systolic BP x diabetes status.

<sup>b</sup>As for multivariate standard model, but with the addition of interaction terms for waist circumference x systolic BP or BMI x systolic BP.

<sup>c</sup>At systolic BP>110mmHg.  
<sup>d</sup>Relative to quintile 2.  
<sup>e</sup>Relative to 18.5≤BMI<25kgm².

<sup>f</sup>The effect of an increment in systolic BP or the indicated obesity category per se.

<sup>g</sup>The additional effect of a 10mmHg increment in systolic BP within each obesity category.
Table 3. Percentage increases in fractional excretion of albumin and ACR with increasing blood pressure, stratified by obesity group and diabetes status.

<table>
<thead>
<tr>
<th>% Increase associated with each 10mmHg increment in systolic BP at &gt;110mmHg</th>
<th>Without Diabetes Mellitus</th>
<th>With Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist circumference quintile</td>
<td>BMI (kg/m²)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>FEalb</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>ACR</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td>Waist circumference quintile</td>
<td>BMI (kg/m²)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>FEalb</td>
<td>17%</td>
<td>16%</td>
</tr>
<tr>
<td>ACR</td>
<td>17%</td>
<td>17%</td>
</tr>
</tbody>
</table>

Results from regression models with interaction terms for sBP x obesity category and sBP x diabetes status.

<sup>a</sup>p<0.05 vs. quintile 2, <sup>b</sup>p<0.001 vs. quintile 2, <sup>c</sup>p<0.005 vs. 18.5≤BMI<25, <sup>d</sup>p<0.05 vs. 18.5≤BMI<25, 
<sup>e</sup>p<0.05 vs. non-diabetic categories

Also adjusted for: systolic and diastolic BP (2-slope model), age, gender, race, diabetes, eGFR, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin antagonists and an interaction term for sBP x eGFR category.
Figure Legends

Figure 1. Odds ratios of moderately increased albuminuria by waist circumference quintile A) in the whole cohort, and B) within subpopulations with systolic BP≥/<110mmHg.

Adjusted for age, gender, race, diabetes, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin inhibitors, CRP, diastolic BP, systolic BP (Figure 1A only), and interaction terms for systolic BP with eGFR and diabetes.

ref, referent group; WC, waist circumference. Error bars represent 95% confidence intervals.

Figure 2. Effects of obesity on the threshold from which increasing systolic BP is accompanied by increasing albumin excretion. In the 5th quintile of waist circumference (A) or at a BMI≥35kg/m² (B), FE Alb increases with systolic BP>110mmHg, whereas for less obese populations (shown for the respective reference categories) there is no increase until systolic BP is >130mmHg. The two-slope regression models for systolic BP were therefore refined, with inflection points at 110mmHg for quintile 5 of waist circumference and BMI≥35kg/m², but at 130mmHg for all other categories. Outputs of the resulting regression models are shown (C,D).

Adjusted for age, gender, race, diabetes, diastolic BP, history of cardiovascular disease, smoking, number of antihypertensives, use of ACEi, use of ARB, use of renin inhibitors, CRP and interaction terms for sBP with eGFR and diabetes.
Figure 1

A

whole cohort

<table>
<thead>
<tr>
<th>Odds Ratio of ACR≥30mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
</tr>
<tr>
<td>0.5</td>
</tr>
</tbody>
</table>

B

systolic BP≥110mmHg (n=18,146)
systolic BP<110mmHg (n=5,564)

<table>
<thead>
<tr>
<th>Odds Ratio of ACR≥30mg/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
</tr>
<tr>
<td>0.5</td>
</tr>
</tbody>
</table>
Figure 2.

A. Fold-change in $F_{E_{\text{alb}}}$ vs. Systolic BP (mmHg)

B. Fold-change in $F_{E_{\text{alb}}}$ vs. Systolic BP (mmHg)

C. $F_{E_{\text{alb}}} \times 10^{-6}$ vs. Systolic BP (mmHg)

D. $F_{E_{\text{alb}}} \times 10^{-6}$ vs. Systolic BP (mmHg)
Figure 1.

163x235mm (300 x 300 DPI)
Figure 2.